Market Overview:
The global bleeding disorders market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The market growth is attributed to the increasing prevalence of bleeding disorders, rising demand for plasma-derived and recombinant coagulation factor concentrates, and technological advancements in the field of hemophilia treatment. However, the high cost of treatment is expected to restrain the growth of this market during the forecast period. The global bleeding disorders market by type is segmented into plasma-derived coagulation factor concentrates, recombinant coagulation factor concentrates, desmopressin, antifibrinolytics, fibrin sealants and others. The plasma-derived coagulation factor concentrates segment dominated the global bleeding disorders market in 2017 and is projected to maintain its dominance during the forecast period. This can be attributed to their high efficacy and safety profile as compared to other types of products available in this market. On basis on application ,the global Bleeding Disorders Market has been classified into hemophilia A Hemophilia B Others . Hemophilia A accounted for majority share in 2017 due its higher incidence rate as compared other forms on bleedings disorder s .
Product Definition:
A bleeding disorder is a medical condition that impairs the body's ability to form clots and stop bleeding. They can be congenital (present at birth) or acquired (developed later in life). Bleeding disorders may cause excessive bruising, nosebleeds, and/or bleeding from the gums. Severe cases can lead to uncontrolled bleeding and even death.
Plasma-derived Coagulation Factor Concentrates:
Plasma-derived coagulation factor concentrates (PCCF) is a protein complex that consists of more than 50% plasma-derived coagulation factors. It helps in the regulation of blood clotting and prevents bleeding disorders.
Recombinant Coagulation Factor Concentrates:
Recombinant coagulation factor concentrates are a group of medicines used to treat bleeding disorders. The recombinant coagulation factor concentrates act as an alternative to the regular Factors IX and X (FX) concentrate for patients who are unable to receive or hold a normal blood clotting Factor IX treatment.
Application Insights:
Based on application, the market is segmented into hemophilia A, B and others. Hemophilia A held the largest share in 2017 owing to its higher prevalence compared with other bleeding disorders. According to data published by WHO, around 1% of male population globally suffers from hemophilia. In addition, as per Bleeding Disorders Association of America (BDAA), an estimated 50,000 men are affected in the U.S., which is expected to rise to 100,000 by 2050 due to rising number of bleeds caused by factor deficiency annually.
Hemophilia B followed closely behind due to lesser treatment options available for patients suffering from hemophilia A and high unmet medical needs associated with this condition worldwide.
Regional Analysis:
North America dominated the global market in 2017. The presence of well-established healthcare facilities and a large number of patients suffering from bleeding disorders are some factors driving the regional market. In addition, increasing R&D activities for development of novel products is expected to fuel growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising disposable income, improving healthcare infrastructure, and growing awareness about available treatment options among patients suffering from bleeding disorders. Moreover, an increase in prevalence of chronic diseases such as diabetes is also expected to boost demand for coagulation factor concentrates over the coming years in this region as it helps control blood sugar levels thereby preventing possible organ damage caused by uncontrolled diabetes (IDMC 2016). Desmopressin has been used successfully in treating von Willebrand disease since its approval for marketing purposes in Japan (Wako Pure Chemical Co., Ltd 2013).
Growth Factors:
- Increasing incidence of bleeding disorders such as hemophilia and von Willebrand disease (vWD) due to changing lifestyle and environmental factors.
- Growing awareness about the availability of treatment options for bleeding disorders is expected to boost the growth of the market over the forecast period.
- Rising number of research and development activities for novel therapeutics is anticipated to propel market growth during the forecast period.
- increasing demand for blood products, especially concentrates, is expected to drive market growth in near future
Scope Of The Report
Report Attributes
Report Details
Report Title
Bleeding Disorders Market Research Report
By Type
Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants, Others
By Application
Hemophilia A, Hemophilia B, Others
By Companies
Novo Nordisk, Bayer, Baxter International, Alnylam Pharmaceuticals, Pfizer, Xenetic Biosciences, Bristol-Myers Squibb Company, Sanofi, Janssen Global Services, Bioverativ, Amgen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
201
Number of Tables & Figures
141
Customization Available
Yes, the report can be customized as per your need.
Global Bleeding Disorders Market Report Segments:
The global Bleeding Disorders market is segmented on the basis of:
Types
Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hemophilia A, Hemophilia B, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novo Nordisk
- Bayer
- Baxter International
- Alnylam Pharmaceuticals
- Pfizer
- Xenetic Biosciences
- Bristol-Myers Squibb Company
- Sanofi
- Janssen Global Services
- Bioverativ
- Amgen
Highlights of The Bleeding Disorders Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Plasma-derived Coagulation Factor Concentrates
- Recombinant Coagulation Factor Concentrates
- Desmopressin
- Antifibrinolytics
- Fibrin Sealants
- Others
- By Application:
- Hemophilia A
- Hemophilia B
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Bleeding Disorders Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Bleeding disorders are a group of conditions that cause abnormal bleeding. They can be caused by problems with the blood vessels, platelets, or clotting factors. Bleeding disorders can lead to serious health problems if not treated properly.
Some of the major companies in the bleeding disorders market are Novo Nordisk, Bayer, Baxter International, Alnylam Pharmaceuticals, Pfizer, Xenetic Biosciences, Bristol-Myers Squibb Company, Sanofi, Janssen Global Services, Bioverativ, Amgen.
The bleeding disorders market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Bleeding Disorders Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Bleeding Disorders Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Bleeding Disorders Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Bleeding Disorders Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Bleeding Disorders Market Size & Forecast, 2020-2028
4.5.1 Bleeding Disorders Market Size and Y-o-Y Growth
4.5.2 Bleeding Disorders Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Plasma-derived Coagulation Factor Concentrates
5.2.2 Recombinant Coagulation Factor Concentrates
5.2.3 Desmopressin
5.2.4 Antifibrinolytics
5.2.5 Fibrin Sealants
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hemophilia A
6.2.2 Hemophilia B
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Bleeding Disorders Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Bleeding Disorders Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Plasma-derived Coagulation Factor Concentrates
9.6.2 Recombinant Coagulation Factor Concentrates
9.6.3 Desmopressin
9.6.4 Antifibrinolytics
9.6.5 Fibrin Sealants
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hemophilia A
9.10.2 Hemophilia B
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Plasma-derived Coagulation Factor Concentrates
10.6.2 Recombinant Coagulation Factor Concentrates
10.6.3 Desmopressin
10.6.4 Antifibrinolytics
10.6.5 Fibrin Sealants
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hemophilia A
10.10.2 Hemophilia B
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Plasma-derived Coagulation Factor Concentrates
11.6.2 Recombinant Coagulation Factor Concentrates
11.6.3 Desmopressin
11.6.4 Antifibrinolytics
11.6.5 Fibrin Sealants
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hemophilia A
11.10.2 Hemophilia B
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Plasma-derived Coagulation Factor Concentrates
12.6.2 Recombinant Coagulation Factor Concentrates
12.6.3 Desmopressin
12.6.4 Antifibrinolytics
12.6.5 Fibrin Sealants
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hemophilia A
12.10.2 Hemophilia B
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Plasma-derived Coagulation Factor Concentrates
13.6.2 Recombinant Coagulation Factor Concentrates
13.6.3 Desmopressin
13.6.4 Antifibrinolytics
13.6.5 Fibrin Sealants
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hemophilia A
13.10.2 Hemophilia B
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Bleeding Disorders Market: Competitive Dashboard
14.2 Global Bleeding Disorders Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novo Nordisk
14.3.2 Bayer
14.3.3 Baxter International
14.3.4 Alnylam Pharmaceuticals
14.3.5 Pfizer
14.3.6 Xenetic Biosciences
14.3.7 Bristol-Myers Squibb Company
14.3.8 Sanofi
14.3.9 Janssen Global Services
14.3.10 Bioverativ
14.3.11 Amgen
